Bionomics Announced The Outcomes Of An End-of-phase 2 Meeting With The FDA For BNC210 For The Acute Treatment Of Social Anxiety Disorder Into Phase 3 Studies; First Patient Dosing In Phase 3 Program Planed For Q1 FY24 - 8K
Portfolio Pulse from Benzinga Newsdesk
Bionomics has announced the outcomes of an end-of-phase 2 meeting with the FDA for BNC210, a drug for the acute treatment of social anxiety disorder. The company plans to move into phase 3 studies, with the first patient dosing planned for Q1 FY24.
October 16, 2023 | 10:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bionomics' announcement of moving BNC210 into phase 3 studies could potentially boost investor confidence in the company's pipeline and future prospects.
The progression of BNC210 into phase 3 studies indicates positive results from the end-of-phase 2 meeting with the FDA. This could increase investor confidence in Bionomics' ability to bring the drug to market, potentially leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100